These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33361702)

  • 1. Therapeutic Potential of
    Oh GM; Moon W; Seo KI; Jung K; Kim JH; Kim SE; Park MI; Park SJ
    Korean J Gastroenterol; 2021 Jan; 77(1):12-21. PubMed ID: 33361702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission.
    Bodini G; Ghezzi A; Pasta A; Marabotto E; Calabrese F; Facchini C; Demarzo MG; Giannini EG
    J Gastrointestin Liver Dis; 2023 Dec; 32(4):438-443. PubMed ID: 38147604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
    Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
    J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
    Scaldaferri F; Gerardi V; Mangiola F; Lopetuso LR; Pizzoferrato M; Petito V; Papa A; Stojanovic J; Poscia A; Cammarota G; Gasbarrini A
    World J Gastroenterol; 2016 Jun; 22(24):5505-11. PubMed ID: 27350728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.
    Park SK; Kang SB; Kim S; Kim TO; Cha JM; Im JP; Choi CH; Kim ES; Seo GS; Eun CS; Han DS; Park DI
    Korean J Intern Med; 2022 Sep; 37(5):949-957. PubMed ID: 36068716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
    Henker J; Müller S; Laass MW; Schreiner A; Schulze J
    Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).
    Matthes H; Krummenerl T; Giensch M; Wolff C; Schulze J
    BMC Complement Altern Med; 2010 Apr; 10():13. PubMed ID: 20398311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
    Losurdo G; Iannone A; Contaldo A; Ierardi E; Di Leo A; Principi M
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):499-505. PubMed ID: 26697577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
    Patel A; Panchal H; Dubinsky MC
    Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
    Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission.
    Guardiola J; Lobatón T; Rodríguez-Alonso L; Ruiz-Cerulla A; Arajol C; Loayza C; Sanjuan X; Sánchez E; Rodríguez-Moranta F
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1865-70. PubMed ID: 24993368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
    Scaioli E; Sartini A; Bellanova M; Campieri M; Festi D; Bazzoli F; Belluzzi A
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1268-1275.e2. PubMed ID: 29391271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission".
    Pasta A; Calabrese F; Bodini G
    J Gastrointestin Liver Dis; 2024 Jun; 33(2):281. PubMed ID: 38944863
    [No Abstract]   [Full Text] [Related]  

  • 17. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study.
    Shimoyama T; Yamamoto T; Umegae S; Matsumoto K
    BMC Gastroenterol; 2018 Aug; 18(1):120. PubMed ID: 30068300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
    Osterman MT; Aberra FN; Cross R; Liakos S; McCabe R; Shafran I; Wolf D; Hardi R; Nessel L; Brensinger C; Gilroy E; Lewis JD;
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1887-93.e3. PubMed ID: 24793028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
    Yamamoto T; Shimoyama T; Matsumoto K
    Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.